Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissueNicola Maurea, Vincenzo Quagliariello, M Passariello et al.|European Heart Journal|2022Cited by 1